case_images: PMC11408163_01
case_images: PMC11408163_02
case_images: Diagnosis of Glioblastoma. Axial (A), coronal (B) and sagittal (C) Diagnostic imaging result. T1-weighted MRI demonstrating a contrast-rim-enhancing lesion of the right temporal lobe. (D) Hematoxylin and eosin stains of the tumor, showing vascular endothelial cell proliferation at 100x.
case_images: fphar-15-1401000-g001.jpg
case_images: PMC11408163_02_fphar-15-1401000-g001.jpg
case_images: F1
case_images: There was appreciable compression of the adjacent brain parenchyma, with concomitant displacement of the intracranial midline structures to the left (Figures 1A-C). Postoperative pathology and genetic examination confirmed the diagnosis of glioblastoma [World Health Organization (WHO) stage IV] (Figure 1D), with an IDH wild-type genotype and a positive methylation status of the MGMT promoter.
case_images: Timeline of treatment and radiographic responses. (A) Timeline of treatment. Abbreviations: Glioblastoma (GBM), partial response (PR), complete response (CR), bevacizumab (BEV), temozolomide (TMZ), stereotactic radiotherapy (SRT); (B, C) The post-contrast T1-weighted MRI showing regression of the lesion and demonstrating the effectiveness of SRT followed by bevacizumab (BEV) and temozolomide (TMZ).
case_images: fphar-15-1401000-g002.jpg
case_images: PMC11408163_02_fphar-15-1401000-g002.jpg
case_images: F2
case_images: Then, postoperative adjuvant radiotherapy (60 Gy in 30 fractions) and temozolomide chemotherapy (75 mg/m2, qd, days 1-42) concurrently were given on 20 July 2020 (Figure 2A). Post-contrast imaging revealed these lesions to exhibit pronounced and irregular "ring-enhancement" patterns, which are suggestive of tumor recurrence (Figures 2B,C dated 2022.01.30). Craniocerebral MRI scans demonstrated a further reduction in tumor foci size, culminating in a final response evaluation of complete response (CR) (Figure 2B 2022.07.6).